LACTOFERRIN TREATMENT OF ASYMPTOMATIC SUBJECTS WITH H PYLORI GASTRITIS

乳铁蛋白治疗无症状幽门螺杆菌胃炎受试者

• 批准号: 6116783
• 负责人: Mark Alan Gilger
• 金额: $ 2.65万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6116783
• 关键词: Helicobacter; clinical research; clinical trials; dosage; drug screening /evaluation; gastritis; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; lactoferrin; microorganism disease chemotherapy

Objective is to determine whether orally administered recombinant lactoferrin, produced in Aspergillis awamori, is a safe and effective agent for the treatment of infectious Helicobacter pylori gastritis. Currently 6 patients have been enrolled, and preliminary evidence shows no side effects although no efficacy has yet been determined. Study will continue with higher dosing to further dvaluate efficacy.

目的是确定是否口服重组 乳铁蛋白是一种安全有效的 用于治疗感染性幽门螺杆菌胃炎的药剂。 目前已入组6例患者，初步证据显示， 没有副作用，但尚未确定疗效。 研究 将继续使用更高的剂量以进一步评估疗效。